Daniele Santini | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report	ONCOLOGY LETTERS	2023
The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets	FRONTIERS IN ONCOLOGY	2023
Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System	NATURE REVIEWS. UROLOGY	2023
Case report: The use of PRP in the treatment of diabetic foot: case series and a review of the literature	FRONTIERS IN ENDOCRINOLOGY	2023
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials	EUROPEAN JOURNAL OF CANCER	2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study	NEOPLASIA	2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study	ECLINICALMEDICINE	2023
Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials	CANCER MEDICINE	2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies	CANCERS	2023
Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline	ESMO OPEN	2023
Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline	ESMO OPEN	2023
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts	CURRENT ONCOLOGY REPORTS	2023
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline	ESMO OPEN	2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study	FRONTIERS IN ONCOLOGY	2023
Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study	JOURNAL OF THE NATIONAL CANCER INSTITUTE	2023
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	JOURNAL OF HEMATOLOGY & ONCOLOGY	2022
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study	ESMO OPEN	2022
Large−scale profiling of extracellular vesicles identified miR−625−5p as a novel biomarker of immunotherapy response in advanced non−small−cell lung cancer patients	CANCERS	2022
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO	CLINICAL COLORECTAL CANCER	2022
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study	CANCER MEDICINE	2022